TheraSphere Japan Pre-Market Study

This study evaluates TheraSphere, a liver-targeted radiation therapy using tiny radioactive beads (yttrium-90 microspheres) delivered directly to liver tumors, in Japanese patients with primary or secondary liver cancer who have not responded to or are not eligible for standard treatments. **You may be eligible if...** - You are over 18 with primary or secondary liver cancer confirmed by imaging or biopsy - Your cancer has not responded to or you are not eligible for standard therapies - Your liver tumor occupies less than 50% of total liver volume - Your liver, kidney, and blood function meet required thresholds - Your life expectancy is at least 3 months - You are in generally good overall health (ECOG 0–1) **You may NOT be eligible if...** - You have received prior liver radiation therapy or yttrium-90 treatment - You have significant fluid buildup in your abdomen (ascites) or liver confusion (encephalopathy grade 2+) - You have active serious infections or are undergoing dialysis - You are pregnant or breastfeeding - You have had bleeding from stomach veins related to liver pressure in the past 3 months - You are participating in another clinical study Talk to your doctor to see if this trial is right for you.